Alumis (ALMS) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Alumis (ALMS) has outperformed Savara (SVRA) over the past year, gaining 58.1% versus a gain of 43.9%. Savara is the larger company by market cap ($1.01 billion vs $926.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | SVRA |
|---|---|---|
| Share price | $7.16 | $4.92 |
| Market cap | $926.76M | $1.01B |
| 1-day change | +2.73% | +1.86% |
| YTD return | -26.64% | -18.41% |
| 1-year return | +58.06% | +43.86% |
| 5-year return | — | +281.40% |
| EPS (TTM) | $-3.86 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $24.05M | — |
| Net income (latest FY) | $-243.32M | $-118.84M |
| Operating margin | -1886.92% | — |
| Net margin | -1011.75% | — |
| 52-week high | $31.35 | $7.01 |
| 52-week low | $4.37 | $3.35 |
| Distance from 52-week high | -77.16% | -29.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +348.74% | +124.80% |
| Average volume | 2.45M | 1.83M |
| Shares outstanding | 129.44M | 205.46M |
| Employees | 237 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALMS has outperformed SVRA by 14.2 percentage points over the past year.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
ALMS vs SVRA FAQ
Which is bigger, Alumis or Savara?
Savara (SVRA) is larger, with a market capitalization of $1.01B compared with $926.76M for Alumis (ALMS).
Which stock has performed better over the past year, ALMS or SVRA?
ALMS returned +58.06% over the past 12 months, compared with +43.86% for SVRA (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.